SI2212297T1 - Inhibitorji protein kinaz - Google Patents
Inhibitorji protein kinazInfo
- Publication number
- SI2212297T1 SI2212297T1 SI200830286T SI200830286T SI2212297T1 SI 2212297 T1 SI2212297 T1 SI 2212297T1 SI 200830286 T SI200830286 T SI 200830286T SI 200830286 T SI200830286 T SI 200830286T SI 2212297 T1 SI2212297 T1 SI 2212297T1
- Authority
- SI
- Slovenia
- Prior art keywords
- diseases
- inhibitors
- protein kinases
- cyclin
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99882107P | 2007-10-12 | 2007-10-12 | |
PCT/EP2008/063715 WO2009047359A1 (en) | 2007-10-12 | 2008-10-13 | Inhibitors of protein kinases |
EP08838451A EP2212297B1 (en) | 2007-10-12 | 2008-10-13 | Inhibitors of protein kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2212297T1 true SI2212297T1 (sl) | 2011-09-30 |
Family
ID=40227837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200830286T SI2212297T1 (sl) | 2007-10-12 | 2008-10-13 | Inhibitorji protein kinaz |
Country Status (19)
Country | Link |
---|---|
US (2) | US8716296B2 (sl) |
EP (1) | EP2212297B1 (sl) |
JP (2) | JP5681855B2 (sl) |
KR (1) | KR20100090772A (sl) |
CN (2) | CN104151293A (sl) |
AT (1) | ATE510827T1 (sl) |
AU (1) | AU2008309517B2 (sl) |
BR (1) | BRPI0818543A2 (sl) |
CA (1) | CA2702008A1 (sl) |
DK (1) | DK2212297T3 (sl) |
EA (1) | EA020439B1 (sl) |
HK (2) | HK1150052A1 (sl) |
HR (1) | HRP20110470T1 (sl) |
IL (1) | IL204594A (sl) |
MX (1) | MX2010003987A (sl) |
NZ (1) | NZ584454A (sl) |
SI (1) | SI2212297T1 (sl) |
WO (1) | WO2009047359A1 (sl) |
ZA (1) | ZA201001910B (sl) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101686685B1 (ko) | 2008-10-31 | 2016-12-14 | 제넨테크, 인크. | 피라졸로피리미딘 jak 억제제 화합물 및 방법 |
US20110230497A1 (en) * | 2008-11-07 | 2011-09-22 | H. Lundbeck A/S | Biologically active amides |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
US9155724B2 (en) | 2010-02-05 | 2015-10-13 | Whitehead Institute For Biomedical Research | Combination methods for treatment of disease |
US8518948B2 (en) | 2010-03-10 | 2013-08-27 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
JP2013107824A (ja) * | 2010-03-17 | 2013-06-06 | Dainippon Sumitomo Pharma Co Ltd | 新規単環ピリミジン誘導体 |
WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
JP5985473B2 (ja) * | 2010-07-13 | 2016-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体 |
WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
CN103339110A (zh) * | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 |
EP2561867A1 (en) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9 inhibitors in the treatment of midline carcinoma |
EP2562265A1 (en) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | Susceptibility to selective CDK9 inhibitors |
ES2650630T3 (es) | 2011-10-03 | 2018-01-19 | The University Of North Carolina At Chapel Hill | Compuestos de pirrolopirimidina para el tratamiento del cáncer |
US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
RS58043B1 (sr) | 2012-04-24 | 2019-02-28 | Vertex Pharma | Inhibitori dna-pk |
EP2852579A4 (en) | 2012-05-22 | 2015-12-30 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER |
US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
EP3527563B1 (en) | 2013-03-12 | 2021-09-01 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2014160017A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
WO2014159999A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Cdk9 kinase inhibitors |
UY35419A (es) | 2013-03-14 | 2014-10-31 | Abbvie Inc | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina |
BR112015023356A2 (pt) | 2013-03-14 | 2017-07-18 | Abbvie Inc | inibidores de quinase pirrol[2,3-b]piridina cdk9 |
WO2014160028A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Pyrrolopyrimindine cdk9 kinase inhibitors |
GB2513403A (en) * | 2013-04-26 | 2014-10-29 | Agency Science Tech & Res | WNT pathway modulators |
SG11201602962PA (en) | 2013-10-17 | 2016-05-30 | Vertex Pharma | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
US9328112B2 (en) | 2014-02-06 | 2016-05-03 | Abbvie Inc. | Tetracyclic CDK9 kinase inhibitors |
WO2015157128A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Therapuetic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity |
WO2015177326A1 (en) | 2014-05-23 | 2015-11-26 | F. Hoffmann-La Roche Ag | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors |
CA3000633C (en) | 2014-10-14 | 2023-10-03 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
US10308648B2 (en) * | 2014-10-16 | 2019-06-04 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
CN107873028B (zh) | 2015-06-29 | 2021-02-02 | 阿斯利康(瑞典)有限公司 | 用作cdk9抑制剂的多环酰胺衍生物 |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
AU2017245641A1 (en) * | 2016-04-07 | 2018-09-13 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridyl derivatives as bromodomain inhibitors |
RU2758669C2 (ru) | 2016-09-27 | 2021-11-01 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк |
BR112019005526A2 (pt) * | 2016-10-20 | 2019-06-18 | Pfizer | agentes antiproliferativos para tratamento de pah |
LT3625228T (lt) | 2017-05-18 | 2021-10-25 | Idorsia Pharmaceuticals Ltd | Pirimidino dariniai, kaip pge2 receptoriaus moduliatoriai |
AR111874A1 (es) | 2017-05-18 | 2019-08-28 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
CR20190559A (es) | 2017-05-18 | 2020-02-10 | Idorsia Pharmaceuticals Ltd | Derivados de fenilo como moduladores del receptor de pge2 |
EP3630766A1 (en) | 2017-05-22 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
CA3063596C (en) * | 2017-05-24 | 2022-08-30 | Abbisko Therapeutics Co., Ltd. | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof |
JP2023505850A (ja) | 2019-12-09 | 2023-02-13 | 石薬集団中奇制薬技術(石家庄)有限公司 | サイクリン依存性キナーゼ9阻害剤としての化合物及びその用途 |
RU2754441C2 (ru) * | 2019-12-30 | 2021-09-02 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
CN115448874A (zh) * | 2021-06-09 | 2022-12-09 | 石药集团中奇制药技术(石家庄)有限公司 | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 |
CN115703760B (zh) * | 2021-08-11 | 2024-05-31 | 山东大学 | 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100521735B1 (ko) | 2000-02-25 | 2005-10-17 | 에프. 호프만-라 로슈 아게 | 아데노신 수용체 조절인자 |
DE10114138C2 (de) | 2001-03-16 | 2003-03-27 | Schering Ag | Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit |
DE10117204A1 (de) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO2002094825A1 (fr) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de spiropiperidine |
DE10129028A1 (de) | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
US20040106647A1 (en) | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
CA2519677A1 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
GB0315966D0 (en) | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
EP1648887A1 (en) | 2003-07-30 | 2006-04-26 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
CA2533474A1 (en) | 2003-07-30 | 2005-02-10 | Shudong Wang | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
EP1679309A4 (en) | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | ANTISTRESS MEDICAMENT AND ITS MEDICAL USE |
WO2005103022A1 (en) | 2004-04-20 | 2005-11-03 | Transtech Pharma, Inc. | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
FR2878247B1 (fr) | 2004-11-19 | 2008-10-03 | Galderma Res & Dev | Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
JP2008542219A (ja) * | 2005-05-25 | 2008-11-27 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | 疼痛処置法 |
-
2008
- 2008-10-13 US US12/226,286 patent/US8716296B2/en not_active Expired - Fee Related
- 2008-10-13 CN CN201410394966.8A patent/CN104151293A/zh active Pending
- 2008-10-13 EA EA201000554A patent/EA020439B1/ru not_active IP Right Cessation
- 2008-10-13 DK DK08838451.6T patent/DK2212297T3/da active
- 2008-10-13 CA CA2702008A patent/CA2702008A1/en not_active Abandoned
- 2008-10-13 NZ NZ584454A patent/NZ584454A/en not_active IP Right Cessation
- 2008-10-13 JP JP2010528428A patent/JP5681855B2/ja not_active Expired - Fee Related
- 2008-10-13 AU AU2008309517A patent/AU2008309517B2/en not_active Ceased
- 2008-10-13 BR BRPI0818543A patent/BRPI0818543A2/pt not_active IP Right Cessation
- 2008-10-13 KR KR1020107010451A patent/KR20100090772A/ko not_active Application Discontinuation
- 2008-10-13 EP EP08838451A patent/EP2212297B1/en not_active Not-in-force
- 2008-10-13 CN CN200880119493.3A patent/CN101889004B/zh not_active Expired - Fee Related
- 2008-10-13 SI SI200830286T patent/SI2212297T1/sl unknown
- 2008-10-13 AT AT08838451T patent/ATE510827T1/de not_active IP Right Cessation
- 2008-10-13 MX MX2010003987A patent/MX2010003987A/es active IP Right Grant
- 2008-10-13 WO PCT/EP2008/063715 patent/WO2009047359A1/en active Application Filing
-
2010
- 2010-03-17 ZA ZA2010/01910A patent/ZA201001910B/en unknown
- 2010-03-18 IL IL204594A patent/IL204594A/en not_active IP Right Cessation
-
2011
- 2011-04-27 HK HK11104221.0A patent/HK1150052A1/xx not_active IP Right Cessation
- 2011-06-24 HR HR20110470T patent/HRP20110470T1/hr unknown
-
2014
- 2014-05-05 US US14/269,703 patent/US20150038516A1/en not_active Abandoned
- 2014-09-03 JP JP2014178745A patent/JP2015038077A/ja active Pending
-
2015
- 2015-05-13 HK HK15104540.0A patent/HK1203950A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0818543A2 (pt) | 2018-10-23 |
IL204594A0 (en) | 2010-11-30 |
AU2008309517B2 (en) | 2013-03-14 |
CN104151293A (zh) | 2014-11-19 |
IL204594A (en) | 2013-12-31 |
EP2212297A1 (en) | 2010-08-04 |
EA020439B1 (ru) | 2014-11-28 |
DK2212297T3 (da) | 2011-09-05 |
US20100249149A1 (en) | 2010-09-30 |
NZ584454A (en) | 2011-09-30 |
EA201000554A1 (ru) | 2011-04-29 |
WO2009047359A1 (en) | 2009-04-16 |
CA2702008A1 (en) | 2009-04-16 |
ATE510827T1 (de) | 2011-06-15 |
JP2015038077A (ja) | 2015-02-26 |
HRP20110470T1 (hr) | 2011-07-31 |
HK1150052A1 (en) | 2011-10-28 |
AU2008309517A1 (en) | 2009-04-16 |
KR20100090772A (ko) | 2010-08-17 |
EP2212297B1 (en) | 2011-05-25 |
JP5681855B2 (ja) | 2015-03-11 |
HK1203950A1 (en) | 2015-11-06 |
US20150038516A1 (en) | 2015-02-05 |
ZA201001910B (en) | 2011-05-25 |
CN101889004A (zh) | 2010-11-17 |
MX2010003987A (es) | 2010-08-04 |
CN101889004B (zh) | 2014-09-10 |
US8716296B2 (en) | 2014-05-06 |
JP2011500539A (ja) | 2011-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203950A1 (en) | Inhibitors of protein kinases | |
WO2009011850A3 (en) | Novel therapeutic compounds | |
MX2012002542A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina. | |
EP2063897A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
EP2063896A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
UA104731C2 (ru) | Ингибиторы р38 мар-киназ | |
TN2011000293A1 (en) | Protein kinase inhibitors | |
EA201070395A1 (ru) | Ингибиторы polo-подобных киназ | |
MY159230A (en) | P38 map kinase inhibitors | |
MX364157B (es) | Compuestos de pirazolo [1,5-a] pirimidina sustituidos como inhibidores de trk cinasa. | |
TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
MX2012004114A (es) | Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1). | |
MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
EA201170052A1 (ru) | Производные тиофена или тиазола и их применение как ингибиторов pi3k | |
MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
EA201201274A1 (ru) | Ингибиторы протеинкиназ | |
EA201170832A1 (ru) | Пуриновые соединения | |
MX340714B (es) | Inhibidores de hsp90. | |
JO2822B1 (en) | Inhibitors of the enzyme kinase P70 S6 and AKT | |
WO2010124121A8 (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor | |
MX2013002851A (es) | Inhibidores de tonum pectinacetilesterasa y metodos de su uso. | |
EA201200891A1 (ru) | Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина | |
BRPI0720050A2 (pt) | 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas |